Get started
BRISTOL-MYERS SQUIBBBRISTOL-MYERS SQUIBBBRISTOL-MYERS SQUIBB

BRISTOL-MYERS SQUIBB

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

1BMY chart


Full chart

Key facts today

Bristol Myers Squibb's Opdivo (nivolumab) is positioned as a competitor to Summit Therapeutics' ivonescimab, which is currently undergoing clinical trials for non-small cell lung cancer.
Analyze the impactAnalyze the impact

1BMY upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪101.69 B‬EUR
Dividend yield (indicated)
4.42%
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.23EUR
Net income (FY)
‪7.27 B‬EUR
Revenue (FY)
‪40.78 B‬EUR
Shares float
‪2.03 B‬
Beta (1Y)
0.00

Employees


Employees (FY)
‪34.1 K‬
Change (1Y)
−200 −0.58%
Revenue / Employee (1Y)
‪1.32 M‬EUR
Net income / Employee (1Y)
‪235.34 K‬EUR

About Bristol-Myers Squibb Company


Sector
Health Technology
CEO
Christopher S. Boerner
Headquarters
Princeton
Website
bms.com
Founded
1933
FIGI
BBG01K3X87N9
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas



See all ideas 

1BMY news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

1BMY highest yielding bonds


C
BMY4036425
Celgene Corporation 5.25% 15-AUG-2043
Yield to maturity
6.45%
Maturity date
Aug 15, 2043
BMY.GC
Bristol-Myers Squibb Company 6.875% 01-AUG-2097
Yield to maturity
6.02%
Maturity date
Aug 1, 2097
C
BMY4275603
Celgene Corporation 5.0% 15-AUG-2045
Yield to maturity
5.94%
Maturity date
Aug 15, 2045
C
BMY3685700
Celgene Corporation 5.7% 15-OCT-2040
Yield to maturity
5.92%
Maturity date
Oct 15, 2040
C
BMY4560589
Celgene Corporation 4.35% 15-NOV-2047
Yield to maturity
5.89%
Maturity date
Nov 15, 2047
US110122EC8
BRIST.MYERS 23/63
Yield to maturity
5.78%
Maturity date
Nov 15, 2063
C
BMY4597874
Celgene Corporation 4.55% 20-FEB-2048
Yield to maturity
5.67%
Maturity date
Feb 20, 2048
US110122EL8
BRIST.MYERS 24/64
Yield to maturity
5.63%
Maturity date
Feb 22, 2064
US110122EB0
BRIST.MYERS 23/53
Yield to maturity
5.61%
Maturity date
Nov 15, 2053
BMY5007349
Bristol-Myers Squibb Company 5.25% 15-AUG-2043
Yield to maturity
5.56%
Maturity date
Aug 15, 2043
US110122EK0
BRIST.MYERS 24/54
Yield to maturity
5.52%
Maturity date
Feb 22, 2054

Explore more bonds 

Sparks


Curated watchlists where 1BMY is featured.

See all sparks 

Frequently Asked Questions


The current price of 1BMY is 50.61 EUR — it has increased by 0.24% in the past 24 hours. Watch BRISTOL-MYERS SQUIBB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange BRISTOL-MYERS SQUIBB stocks are traded under the ticker 1BMY.
1BMY stock has risen by 4.58% compared to the previous week, the month change is a 3.20% rise, over the last year BRISTOL-MYERS SQUIBB has showed a 5.99% increase.
We've gathered analysts' opinions on BRISTOL-MYERS SQUIBB future price: according to them, 1BMY price has a max estimate of 59.07 EUR and a min estimate of 33.23 EUR. Watch 1BMY chart and read a more detailed BRISTOL-MYERS SQUIBB stock forecast: see what analysts think of BRISTOL-MYERS SQUIBB and suggest that you do with its stocks.
1BMY reached its all-time high on Mar 28, 2024 with the price of 50.10 EUR, and its all-time low was 36.00 EUR and was reached on Jul 4, 2024. View more price dynamics on 1BMY chart.
See other stocks reaching their highest and lowest prices.
1BMY stock is 0.24% volatile and has beta coefficient of 0.00. Track BRISTOL-MYERS SQUIBB stock price on the chart and check out the list of the most volatile stocks — is BRISTOL-MYERS SQUIBB there?
Today BRISTOL-MYERS SQUIBB has the market capitalization of ‪101.30 B‬, it has decreased by −0.77% over the last week.
Yes, you can track BRISTOL-MYERS SQUIBB financials in yearly and quarterly reports right on TradingView.
BRISTOL-MYERS SQUIBB is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
1BMY earnings for the last quarter are 1.62 EUR per share, whereas the estimation was 1.34 EUR resulting in a 20.47% surprise. The estimated earnings for the next quarter are 1.36 EUR per share. See more details about BRISTOL-MYERS SQUIBB earnings.
BRISTOL-MYERS SQUIBB revenue for the last quarter amounts to ‪10.68 B‬ EUR, despite the estimated figure of ‪10.12 B‬ EUR. In the next quarter, revenue is expected to reach ‪10.61 B‬ EUR.
1BMY net income for the last quarter is ‪1.09 B‬ EUR, while the quarter before that showed ‪1.57 B‬ EUR of net income which accounts for −30.65% change. Track more BRISTOL-MYERS SQUIBB financial stats to get the full picture.
Yes, 1BMY dividends are paid quarterly. The last dividend per share was 0.55 EUR. As of today, Dividend Yield (TTM)% is 4.42%. Tracking BRISTOL-MYERS SQUIBB dividends might help you take more informed decisions.
BRISTOL-MYERS SQUIBB dividend yield was 4.50% in 2023, and payout ratio reached 59.82%. The year before the numbers were 3.04% and 74.28% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 5, 2024, the company has ‪34.10 K‬ employees. See our rating of the largest employees — is BRISTOL-MYERS SQUIBB on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BRISTOL-MYERS SQUIBB EBITDA is ‪16.62 B‬ EUR, and current EBITDA margin is 40.62%. See more stats in BRISTOL-MYERS SQUIBB financial statements.
Like other stocks, 1BMY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BRISTOL-MYERS SQUIBB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BRISTOL-MYERS SQUIBB technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BRISTOL-MYERS SQUIBB stock shows the strong buy signal. See more of BRISTOL-MYERS SQUIBB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.